论文信息 - A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. - 字舞流文

A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

L. Carey | W. Symmans | M. Goetz | N. Tung | K. Ballman | V. Borges | A. Partridge | T. Zemla | L. Mccall | I. Krop | A. Weiss | Myounghee Lee | C. O'Sullivan | W. Irvin | V. Blinder | M. Mitchell